These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37986143)

  • 1. The efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis.
    Wang Z; Li X; Li M; Peng J; Zhang H
    BMC Cardiovasc Disord; 2023 Nov; 23(1):569. PubMed ID: 37986143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
    Kuang HY; Li Q; Du HA; Chen M; Yin YH
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):181-191. PubMed ID: 32918210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 4. The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis.
    Kuang HY; Wu YH; Yi QJ; Tian J; Wu C; Shou WN; Lu TW
    Medicine (Baltimore); 2018 Mar; 97(10):e0075. PubMed ID: 29517668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis.
    Farmakis IT; Vazakidis P; Doundoulakis I; Arvanitaki A; Zafeiropoulos S; Boutou A; Karvounis H; Giannakoulas G
    Pulm Pharmacol Ther; 2021 Jun; 68():102036. PubMed ID: 33979684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis.
    Yasuhara J; Watanabe K; Watanabe A; Shirasu T; Matsuzaki Y; Watanabe H; Takagi H; Sumitomo N; Kuno T
    Cardiol Young; 2023 Nov; 33(11):2297-2311. PubMed ID: 36721907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
    Barnes H; Brown Z; Burns A; Williams T
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of treat-and-repair strategy for atrial septal defect with pulmonary arterial hypertension.
    Takaya Y; Akagi T; Sakamoto I; Kanazawa H; Nakazawa G; Murakami T; Yao A; Nanasato M; Saji M; Hirokami M; Fuku Y; Hosokawa S; Tada N; Matsumoto K; Imai M; Nakagawa K; Ito H
    Heart; 2022 Mar; 108(5):382-387. PubMed ID: 34415851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Therapies in Patients with Pulmonary Arterial Hypertension Due to Congenital Heart Disease.
    Mares A; Mukherjee D; Lange RA; Nickel NP
    Curr Vasc Pharmacol; 2022; 20(4):341-360. PubMed ID: 36125818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
    Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
    Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability evaluation of oral bosentan in adult congenital heart disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
    Guo L; Liu YJ; Xie ZL
    Eur Rev Med Pharmacol Sci; 2014; 18(5):638-45. PubMed ID: 24668703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Connective Tissue Growth Factor as a Biomarker of Pulmonary Arterial Hypertension Associated With Congenital Heart Disease in Adults.
    Liu W; Hua Y; Zheng D; Lv W; Zhang W; Chen Q; Huang R; Li X
    Circ J; 2023 Mar; 87(4):527-535. PubMed ID: 36843115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic Evaluation of Children with Persistent or Recurrent Pulmonary Arterial Hypertension Following Complete Repair of Congenital Heart Disease.
    Latus H; Wagner I; Ostermayer S; Kerst G; Kreuder J; Schranz D; Apitz C
    Pediatr Cardiol; 2017 Oct; 38(7):1342-1349. PubMed ID: 28681131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy in Congenital Heart Disease, Complicated by Pulmonary Arterial Hypertension-A Challenging Issue for the Pregnant Woman, the Foetus, and Healthcare Professionals.
    Rudienė V; Kaplerienė L; Jančauskaitė D; Meškėnė E; Palevičiūtė E; Laukytė-Slėnienė M; Gasiūnaitė D; Ramašauskaitė D; Jurevičienė E; Gumbienė L
    Medicina (Kaunas); 2022 Mar; 58(4):. PubMed ID: 35454315
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics.
    Jin N; Yu M; Du X; Wu Z; Zhai C; Pan H; Gu J; Xie B
    BMC Cardiovasc Disord; 2023 Mar; 23(1):167. PubMed ID: 36991345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.
    Deng X; Jin B; Li S; Li Y; Zhou H; Wu Y; Yan M; Hu Y; Qiu Q; Zhang G; Zheng X
    Clin Respir J; 2019 Nov; 13(11):693-699. PubMed ID: 31419027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of pulmonary arterial pressure in patients with connective tissue disease-associated pulmonary arterial hypertension by myocardial perfusion imaging.
    Wang Z; Li J; Wang X; Liu M; Liao M; Zhang C; Shang X
    Ann Noninvasive Electrocardiol; 2022 Mar; 27(2):e12927. PubMed ID: 34908208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary vasodilators can lead to various complications in pulmonary "arterial" hypertension associated with congenital heart disease.
    Chida-Nagai A; Sagawa K; Tsujioka T; Fujimoto T; Taniguchi K; Sasaki O; Izumi G; Yamazawa H; Masaki N; Manabe A; Takeda A
    Heart Vessels; 2020 Sep; 35(9):1307-1315. PubMed ID: 32285188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of composite clinical worsening events on outcome of patients with pulmonary arterial hypertension associated with congenital heart disease].
    Xu ZY; Zhang HS; Li QQ; Zhang C; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Mar; 50(3):282-288. PubMed ID: 35340148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.